Drug Profile
Adipose-derived autologous stem cell therapy - U.S. Stem Cell
Alternative Names: AdipoCell (Bioheart); Bioheart Acute Cell Therapy; Implanted autologous adipose-derived stem cells - U.S. Stem Cell; LipiCellLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Bioheart
- Developer Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
- Class Anti-ischaemics; Cardiovascular therapies; Erectile dysfunction therapies; Eye disorder therapies; Heart failure therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Intervertebral disc degeneration
- Phase I/II Heart failure
- No development reported Chronic obstructive pulmonary disease; Coronary disorders; Erectile dysfunction; Meniscus disorders; Myocardial infarction; Myocardial ischaemia; Osteoarthritis; Peripheral ischaemia; Psoriasis
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Meniscus disorder in USA (Injection)
- 28 Feb 2021 No recent reports of development identified for clinical-Phase-Unknown development in Psoriasis in Unknown (IV)
- 19 Oct 2020 Tissue Genesis has been acquired by Orgenesis